BIOXYTRAN, INC. Files Form 10-Q/A Amendment No. 1 for Q1 2024

TL;DR

<b>BIOXYTRAN, INC. filed an amendment to its Q1 2024 quarterly report, confirming its status as a smaller reporting company trading on OTCQB.</b>

AI Summary

BIOXYTRAN, INC (BIXT) filed a Amended Quarterly Report (10-Q/A) with the SEC on April 22, 2024. BIOXYTRAN, INC. filed an amendment (10-Q/A) to its quarterly report for the period ended March 31, 2024. The company is incorporated in Nevada and operates under SIC code 2834 (Pharmaceutical Preparations). Its common stock trades under the symbol BIXT on the OTCQB exchange. BIOXYTRAN, INC. was formerly known as U.S. RARE EARTH MINERALS, INC. and U.S. Natural Nutrients & Minerals, Inc. The filing indicates the company is a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking BIOXYTRAN, INC, this filing contains several important signals. This amendment provides updated financial and operational information for the first quarter of 2024, crucial for investors to assess the company's current performance and outlook. The confirmation of its status as a smaller reporting company and non-accelerated filer provides context for the level of detail and regulatory scrutiny expected in its filings.

Risk Assessment

Risk Level: low — BIOXYTRAN, INC shows low risk based on this filing. The filing is an amendment to a quarterly report, indicating a routine update rather than a significant event, and no immediate financial or operational crises are highlighted.

Analyst Insight

Investors should review the amended Q1 2024 filing for updated financial details and operational disclosures from BIOXYTRAN, INC.

Key Numbers

• 2024-03-31 — Quarterly Period End Date (Conformed period of report)
• 2024-04-22 — Filing Date (Filed as of date)
• 001-35027 — Commission File Number (SEC file number)
• 2834 — SIC Code (Primary Standard Industrial Classification Code Number)

Key Players & Entities

• BIOXYTRAN, INC. (company) — Registrant name
• BIXT (company) — Trading Symbol
• 2024-03-31 (date) — Conformed period of report
• 2024-04-22 (date) — Filed as of date
• 001-35027 (company) — Commission file number
• 2834 (company) — Standard Industrial Classification
• Nevada (company) — State of incorporation
• U.S. RARE EARTH MINERALS, INC. (company) — Former company name

FAQ

Industry Context

BIOXYTRAN, INC. operates in the Pharmaceutical Preparations industry (SIC 2834).

Regulatory Implications

The company is subject to SEC reporting requirements under the Securities Exchange Act of 1934, including filing quarterly reports (Form 10-Q).

What Investors Should Do

1. Review the full amended 10-Q filing for detailed financial statements and management discussion.
2. Monitor future filings for updates on the company's performance and strategic initiatives.
3. Research the company's historical filings and market performance on OTCQB.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q/A filing.
• 2024-04-22: Filing Date — Date the amendment was filed with the SEC.

Year-Over-Year Comparison

This is an amendment (10-Q/A) to the quarterly report for the period ended March 31, 2024, indicating an update to previously filed information.

Key Financial Figures

• $18,000 — f Common Stock for a cash investment of $18,000, or $0.104/share. $4,000 of these funds
• $0.104 — ck for a cash investment of $18,000, or $0.104/share. $4,000 of these funds were inclu
• $4,000 — investment of $18,000, or $0.104/share. $4,000 of these funds were included as unissue
• $61,500 — Common Stock in conversion of a note of $61,500 and $795 in interest, or $0.13/share.
• $795 — in conversion of a note of $61,500 and $795 in interest, or $0.13/share. Shares A
• $0.13 — ote of $61,500 and $795 in interest, or $0.13/share. Shares Awarded under the 2021
• $104,000 — ns agreement. The shares fair value was $104,000, or $0.104/share. On April 5, 2024 th
• $50 — uance of 50,000 made on March 27, 2023. $50 was transferred from Common Stock to AP
• $30,000 — 024. The fair value of these shares was $30,000, or $0.124/share. The issuance was incl
• $0.124 — r value of these shares was $30,000, or $0.124/share. The issuance was included as uni
• $10,246 — 024. The fair value of these shares was $10,246, or $0.124/share. The issuance was incl

Filing Documents

• form10-qa.htm (10-Q/A) — 57KB
• ex31-1.htm (EX-31.1) — 7KB
• ex31-2.htm (EX-31.2) — 7KB
• 0001493152-24-015525.txt (&nbsp;) — 357KB
• bixt-20240331.xsd (EX-101.SCH) — 25KB
• bixt-20240331_lab.xml (EX-101.LAB) — 97KB
• bixt-20240331_pre.xml (EX-101.PRE) — 22KB
• form10-qa_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to _____________ Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of registrant as specified in its charter) Nevada 2834 26-2797630 (State or other jurisdiction of incorporation or organization) (Primary (I.R.S. Employer Identification No.) 75 2nd Avenue , Ste 605 , Needham , MA 02494 (Address of principal executive offices) (Zip Code) 617 - 454-1199 (Registrant's telephone number, including area code) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BIXT OTCQB Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to 240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The amount of registered shares of the registrant's Common Stock as of April 19, 2024 was 174,962,481 . Explanatory Note This Amendment No. 1 to the Quarterly Report on Form 10-Q of Bioxytran, Inc. for the quarter ended March 31, 2024, originally filed on April 19, 2024 (the "Original Filing"), is being filed solely to correct Note 12 to the Financial Statements in the original filing. Inadvertently, the month of May was incorrectly stated, instead of the month of April. Note 12 - Subsequent Events, of this Amendment No. 1, has been restated with the actual month of issuance for the shares of Common Stock. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Form 10-Q/A also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been included in this Form 10-Q/A and this Form 10-Q/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Except as described above, no other changes have been made to the Original Filing, and this Form 10-Q/A does not modify, amend or update in any way any of the financial or other information contained in the Original Filing. This Form 10-Q/A does not reflect events that may have occurred subsequent to the filing date of the Original Filing. BIOXYTRAN, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS IN THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED) NOTE 12 – SUBSEQUENT EVENTS The Company has evaluated events from March 31, 2024 through the date the financial statements were issued. The events requiring disclosure for this period are as follows; Remuneration Adjustment by Management Team The management team will reduce their compensation with 67% for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever c

View Full Filing

View this 10-Q/A filing on SEC EDGAR